Diabetes Leaders Lilly, Sanofi Give A Glimpse Of GLP-1 Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi and Lilly, latecomers to the rising class of GLP-1 diabetes drugs, may not have much to differentiate their drugs from other offerings. But at investor forums at the American Diabetes Association meeting, they highlighted some possibilities, including hypertension data and combination therapies.
You may also be interested in...
GLP1 Diabetes Showdown Nears As Lyxumia Gets Green Light In Europe
The EU's Committee for Medicinal Products for Human Use has recommended two Sanofi products - the diabetes therapy Lyxumia and the colorectal cancer drug Zaltrap – while also backing the first vaccine in Europe for meningitis B, Novartis' Bexsero.
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership
The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.